Overview

Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lenalidomide may stop the growth of solid tumors by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with docetaxel and carboplatin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with docetaxel and carboplatin in treating patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
The Cleveland Clinic
Collaborator:
National Cancer Institute (NCI)
Treatments:
Carboplatin
Docetaxel
Lenalidomide